GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (NAS:PRTG) » Definitions » E10

PRTG (Portage Biotech) E10 : $79.51 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Portage Biotech E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Portage Biotech's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.260. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $79.51 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Portage Biotech's average E10 Growth Rate was -2.90% per year. During the past 3 years, the average E10 Growth Rate was 0.70% per year. During the past 5 years, the average E10 Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Portage Biotech was 39.40% per year. The lowest was 0.70% per year. And the median was 22.40% per year.

As of today (2024-12-14), Portage Biotech's current stock price is $3.00. Portage Biotech's E10 for the quarter that ended in Sep. 2024 was $79.51. Portage Biotech's Shiller PE Ratio of today is 0.04.

During the past 13 years, the highest Shiller PE Ratio of Portage Biotech was 9.39. The lowest was 0.00. And the median was 0.00.


Portage Biotech E10 Historical Data

The historical data trend for Portage Biotech's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech E10 Chart

Portage Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.74 78.33 90.69 87.94 79.87

Portage Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.90 78.21 79.87 78.27 79.51

Competitive Comparison of Portage Biotech's E10

For the Biotechnology subindustry, Portage Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portage Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Shiller PE Ratio falls into.



Portage Biotech E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Portage Biotech's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.26/133.0289*133.0289
=-1.260

Current CPI (Sep. 2024) = 133.0289.

Portage Biotech Quarterly Data

per share eps CPI Adj_EPS
201412 -6.208 99.070 -8.336
201503 -20.000 99.621 -26.707
201506 -7.201 100.684 -9.514
201509 -8.273 100.392 -10.963
201512 -20.000 99.792 -26.661
201603 0.000 100.470 0.000
201606 -20.000 101.688 -26.164
201609 260.000 101.861 339.556
201612 -40.000 101.863 -52.239
201703 -80.000 102.862 -103.462
201706 -2.544 103.349 -3.275
201709 -2.584 104.136 -3.301
201712 -2.651 104.011 -3.391
201803 925.580 105.290 1,169.432
201806 -1.560 106.317 -1.952
201809 -1.489 106.507 -1.860
201812 -2.187 105.998 -2.745
201903 -3.544 107.251 -4.396
201906 -2.600 108.070 -3.200
201909 -2.400 108.329 -2.947
201912 -2.400 108.420 -2.945
202003 -2.400 108.902 -2.932
202006 -1.200 108.767 -1.468
202009 -4.200 109.815 -5.088
202012 -2.000 109.897 -2.421
202103 -19.600 111.754 -23.331
202106 -5.000 114.631 -5.802
202109 -4.400 115.734 -5.058
202112 -5.200 117.630 -5.881
202203 -11.000 121.301 -12.064
202206 -2.600 125.017 -2.767
202209 -1.200 125.227 -1.275
202212 -8.800 125.222 -9.349
202303 -116.800 127.348 -122.011
202306 -133.800 128.729 -138.270
202309 -5.800 129.860 -5.942
202312 -37.600 129.419 -38.649
202403 -24.200 131.776 -24.430
202406 -31.600 132.554 -31.713
202409 -1.260 133.029 -1.260

Add all the adjusted EPS together and divide 10 will get our e10.


Portage Biotech  (NAS:PRTG) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Portage Biotech's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=3.00/79.51
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Portage Biotech was 9.39. The lowest was 0.00. And the median was 0.00.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Portage Biotech E10 Related Terms

Thank you for viewing the detailed overview of Portage Biotech's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Portage Biotech Business Description

Traded in Other Exchanges
N/A
Address
Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.